Trevi Therapeutics (TRVI) CFO reports Form 3 showing no stock
Rhea-AI Filing Summary
Trevi Therapeutics, Inc. executive David C. Hastings, the company’s Chief Financial Officer, filed an initial Form 3 ownership report as of 01/08/2026.
The filing indicates that he has no securities beneficially owned in Trevi Therapeutics, with both the non-derivative and derivative securities tables showing no holdings. A power of attorney (Exhibit 24.1) authorizes attorney-in-fact Christopher Galletta to sign the form on his behalf.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does Trevi Therapeutics (TRVI) disclose in this Form 3 filing?
The Form 3 shows that Chief Financial Officer David C. Hastings currently has no securities beneficially owned in Trevi Therapeutics, Inc.
Who is the reporting person in Trevi Therapeutics (TRVI) Form 3?
The reporting person is David C. Hastings, who is identified as an officer of Trevi Therapeutics, serving as Chief Financial Officer.
What is the event date for the Trevi Therapeutics (TRVI) Form 3?
The Form 3 lists the Date of Event Requiring Statement as 01/08/2026.
Does the Trevi Therapeutics (TRVI) CFO own any non-derivative or derivative securities?
No. The filing states in the remarks that no securities are beneficially owned, and the tables for non-derivative and derivative securities show no holdings.
Who signed the Trevi Therapeutics (TRVI) Form 3 on behalf of the CFO?
The Form 3 is signed by /s/ Christopher Galletta as attorney-in-fact, pursuant to a Power of Attorney listed as Exhibit 24.1.
Is this Trevi Therapeutics (TRVI) Form 3 filed by one or multiple reporting persons?
The document indicates that it is a Form filed by One Reporting Person, referring to David C. Hastings.